CN108473500B - 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 - Google Patents

用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 Download PDF

Info

Publication number
CN108473500B
CN108473500B CN201680079065.7A CN201680079065A CN108473500B CN 108473500 B CN108473500 B CN 108473500B CN 201680079065 A CN201680079065 A CN 201680079065A CN 108473500 B CN108473500 B CN 108473500B
Authority
CN
China
Prior art keywords
alkyl
group
heteroaryl
bicyclic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680079065.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108473500A (zh
Inventor
D·S·温斯坦
R·M·莫斯林
Y·张
D·S·加德纳
J·B·圣泰拉
C·M·兰格维内
S·斯达胡拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN108473500A publication Critical patent/CN108473500A/zh
Application granted granted Critical
Publication of CN108473500B publication Critical patent/CN108473500B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680079065.7A 2015-11-18 2016-11-17 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 Active CN108473500B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562256784P 2015-11-18 2015-11-18
US62/256,784 2015-11-18
US201662404827P 2016-10-06 2016-10-06
US62/404,827 2016-10-06
PCT/US2016/062396 WO2017087590A1 (en) 2015-11-18 2016-11-17 Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Publications (2)

Publication Number Publication Date
CN108473500A CN108473500A (zh) 2018-08-31
CN108473500B true CN108473500B (zh) 2021-06-08

Family

ID=57472068

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680079065.7A Active CN108473500B (zh) 2015-11-18 2016-11-17 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物

Country Status (7)

Country Link
US (1) US10479793B2 (enExample)
EP (1) EP3377496B1 (enExample)
JP (1) JP6843135B2 (enExample)
KR (1) KR102782807B1 (enExample)
CN (1) CN108473500B (enExample)
ES (1) ES2828733T3 (enExample)
WO (1) WO2017087590A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3215511T3 (da) 2014-11-06 2024-05-13 Bial R&D Invest S A Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
CA2966581A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
WO2017176962A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP7046827B2 (ja) 2016-04-06 2022-04-04 リソソーマル・セラピューティクス・インコーポレイテッド イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
WO2017176960A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
BR112018072552A8 (pt) * 2016-05-05 2023-03-14 Lysosomal Therapeutics Inc Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos
MA46453A (fr) * 2016-10-07 2019-08-14 Bristol Myers Squibb Co Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha
ES2849974T3 (es) * 2016-11-17 2021-08-24 Bristol Myers Squibb Co Moduladores de imidazopiridazina de IL-12, IL-23 y/o IFNalfa
US11046698B2 (en) * 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
US11891400B2 (en) 2018-09-10 2024-02-06 Eli Lilly And Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
KR102850357B1 (ko) 2018-10-22 2025-08-27 알루미스 인크. Tyk2 억제제 및 이의 용도
TWI800696B (zh) * 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
CA3126034A1 (en) * 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
BR112021015616A2 (pt) * 2019-02-07 2021-11-09 Ventyx Biosciences Inc Ligantes de pseudoquinase tyk2
EP3935058B1 (en) * 2019-03-05 2024-08-21 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
AU2020239026B2 (en) * 2019-03-11 2025-10-09 Alumis Inc. TYK2 inhibitors and uses thereof
AR121251A1 (es) * 2020-02-12 2022-05-04 Lilly Co Eli Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida
US11691979B2 (en) * 2020-04-30 2023-07-04 Janssen Pharmaceutica Nv Imidazopyridazines as modulators of IL-17
KR20230018387A (ko) * 2020-04-30 2023-02-07 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리미딘
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022037694A1 (zh) * 2020-08-20 2022-02-24 轶诺(浙江)药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
AU2021345181A1 (en) * 2020-09-16 2023-05-04 Alumis Inc Tyk2 inhibitors and uses thereof
US20240246944A1 (en) 2021-03-16 2024-07-25 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
US20250051338A1 (en) 2021-10-25 2025-02-13 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CN118159524B (zh) * 2022-01-28 2024-12-17 和记黄埔医药（上海）有限公司 咪唑并[1,2-b]哒嗪类化合物的中间体的合成方法
WO2025168035A1 (zh) * 2024-02-07 2025-08-14 合肥羿科医药有限公司 杂环类化合物、其药物组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
EP2217601A1 (en) * 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
CN104394869A (zh) * 2011-10-20 2015-03-04 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
EP2822559B1 (en) * 2012-03-09 2018-05-02 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa

Also Published As

Publication number Publication date
KR102782807B1 (ko) 2025-03-14
EP3377496A1 (en) 2018-09-26
KR20180081584A (ko) 2018-07-16
US20180325899A1 (en) 2018-11-15
CN108473500A (zh) 2018-08-31
WO2017087590A1 (en) 2017-05-26
JP6843135B2 (ja) 2021-03-17
US10479793B2 (en) 2019-11-19
JP2019501125A (ja) 2019-01-17
ES2828733T3 (es) 2021-05-27
EP3377496B1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
CN108473500B (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
AU2023255024B2 (en) Sulfone pyridine alkyl amide-substituted heteroaryl compounds
CN110036015B (zh) 可用作IL-12、IL-23和/或IFNα应答的调节剂的咪唑并哒嗪化合物
AU2014347275B2 (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses
EP3917912B1 (en) Amide-disubstituted pyridine or pyridazine compounds
AU2019373203A1 (en) Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
CN104903301B (zh) 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物
WO2021222153A1 (en) Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators
CN110191887B (zh) IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
EP4337656A1 (en) Substituted heterocyclic compounds
WO2018111787A1 (en) Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses
CN114222744B (zh) 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物
HK1226400B (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant